Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab Consolidation with Neoadjuvant Chemo-IO ± Bevacizumab in NSCLC
NCT05468242Phase 2Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Jan 2022
- Primary completion
- Dec 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tislelizumab and bevacizumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Sun Yat-sen University. Primary endpoint: Progression free survival at 2 years. Started Jan 2022; status: recruiting.
02
Drugs
tislelizumabbevacizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05468242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05468242.